title: Clinical value of routine serum squamous cell carcinoma antigen in follow-up of patients with early-stage cervical cancer.
abstract: OBJECTIVE
  To investigate the contribution to recurrence detection and survival of serum squamous cell carcinoma antigen (SCC-ag) analysis in the follow-up of early-stage cervical cancer patients.
  
  
  METHODS
  Follow-up data were evaluated in patients with early-stage squamous cell cervical cancer treated by radical hysterectomy and pelvic lymphadenectomy with or without radiotherapy. Routine serum SCC-ag determination was performed at each follow-up visit.
  
  
  RESULTS
  Recurrent disease occurred in 35 (16%) of 225 patients and was preceded or accompanied by serum SCC-ag elevation 26 times (sensitivity, 74%). In five (14%) of these 35 patients, elevated serum SCC-ag was the first measured clinical indicator. Desite salvage therapy, all five patients died of disease. In the other 31 patients (21 with serum SCC-ag elevation), either symptoms and/or positive signs led to recurrence detection. Median survival time after recurrence was worse (9 months; range, 2 to 112+) for patients with an elevated serum SCC-ag value at recurrence in comparison with patients with normal serum SCC-ag values (20 months; range, 4 to 96; P <.01). In 23 of the 190 patients without recurrences, serum SCC-ag values became falsely elevated. In 16 of these 23 patients, the repeat sample after 6 weeks showed a normal SCC-ag, and in seven patients benign (especially skin) disorders were found.
  
  
  CONCLUSIONS
  Serum SCC-ag analysis results in earlier recurrence detection in a small proportion (14%) of patients but did not contribute to better survival. As long as treatment possibilities for recurrent cervical cancer patients are not improved, serum SCC-ag analysis should not be carried out in routine follow-up.
authors.affiliation: Department of Obstetrics and Gynecology, University Hospital Groningen, Groningen, The Netherlands.
authors.forename: M D
authors.initials: MD
authors.lastname: Esajas
authors.forename: J M
authors.initials: JM
authors.lastname: Duk
authors.forename: H W
authors.initials: HW
authors.lastname: de Bruijn
authors.forename: J G
authors.initials: JG
authors.lastname: Aalders
authors.forename: P H
authors.initials: PH
authors.lastname: Willemse
authors.forename: W
authors.initials: W
authors.lastname: Sluiter
authors.forename: B
authors.initials: B
authors.lastname: Pras
authors.forename: K
authors.initials: K
authors.lastname: ten Hoor
authors.forename: H
authors.initials: H
authors.lastname: Hollema
authors.forename: A G
authors.initials: AG
authors.lastname: van der Zee
mesh_terms: D000951:Antigens, Neoplasm / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D002294:Carcinoma, Squamous Cell / Q000276:immunology* / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000276:immunology; D015843:Serpins; D002583:Uterine Cervical Neoplasms / Q000276:immunology* / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery
chemical_list: D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D015843:Serpins; C051072:squamous cell carcinoma-related antigen